Contrasting Endonovo Therapeutics (OTCMKTS:ENDV) and NeurAxis (NASDAQ:NRXS)

Endonovo Therapeutics (OTCMKTS:ENDV) and NeurAxis (NASDAQ:NRXS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk and dividends.

Insider and Institutional Ownership

11.8% of NeurAxis shares are held by institutional investors. 5.6% of Endonovo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Endonovo Therapeutics and NeurAxis’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Endonovo Therapeutics	4,911.97%	-29.58%	755.18%
NeurAxis	-594.55%	N/A	-899.27%

Analyst Recommendations

This is a breakdown of recent recommendations for Endonovo Therapeutics and NeurAxis, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Endonovo Therapeutics	0	0	0	0	N/A
NeurAxis	0	0	1	0	3.00

Earnings and Valuation

This table compares Endonovo Therapeutics and NeurAxis’ top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Endonovo Therapeutics	$140,000.00	6.24	$6.93 million	N/A	N/A
NeurAxis	$2.46 million	8.60	-$14.63 million	($4.59)	-0.70

Endonovo Therapeutics has higher earnings, but lower revenue than NeurAxis.

Summary

NeurAxis beats Endonovo Therapeutics on 5 of the 9 factors compared between the two stocks.

About Endonovo Therapeutics

Endonovo Therapeutics, Inc., a biotechnology company, develops, manufactures, and distributes non-invasive Electroceutical medical devices for regenerative medicine. The company offers SofPulse, a non-invasive Electroceutical therapeutic device for the palliative treatment of soft tissue injuries, chronic wounds, and post-operative pain and edema. Its Electroceuticals medical device is also used for the treatment of cardiovascular diseases, chronic kidney, liver diseases, non-alcoholic steatohepatitis, cardiovascular and peripheral artery diseases, and ischemic stroke, as well as for central nervous system disorders, such as traumatic brain injury, acute concussions, post-concussion syndrome, stroke, and multiple sclerosis. Endonovo Therapeutics, Inc. was founded in 2008 and is based in Woodland Hills, California.

About NeurAxis

NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.